Communiqués Assembly Biosciences, Inc.

Actions

ASMB

US0453962070

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/07/2026			Varia. 5j.	Varia. 1 janv.
25,11 ^USD	-3,65%		-1,72%	-26,17%

15/06	ASSEMBLY BIOSCIENCES, INC. : Mizuho Securities maintient sa recommandation à l'achat	ZM
08/06	Transcript : Assembly Biosciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 08:40 AM

Communiqués

28/05	Assembly Biosciences Announces Upcoming Investor Conference Presentations	AQ
26/05	Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares	AQ
22/05	Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants	AQ
22/05	Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases	AQ
13/05	Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026	AQ
11/05	Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference	AQ
08/05	Assembly Biosciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
08/05	Assembly Biosciences : Corporate Presentation (ffa6e6)	PU
07/05	Assembly Biosciences: Q1 Earnings Snapshot	AQ
07/05	Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights	AQ
09/04	Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026	AQ
19/03	Assembly Biosciences: Q4 Earnings Snapshot	AQ
19/03	Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights	AQ
09/12	Assembly Biosciences : Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 in Recurrent Genital Herpes	PU
08/12	Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes	AQ
10/11	Assembly Biosciences: Q3 Earnings Snapshot	AQ
10/11	Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates	AQ
07/11	Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®	AQ
14/10/25	Assembly Biosciences Announces Upcoming Investor Conference Participation	AQ
13/10/25	Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase, Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union against Sexually Transmitted Infections, Europe	AQ
10/10/25	Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe	AQ
12/08/25	Assembly Biosciences Announces Pricing of $175 Million in Equity Financings	AQ
08/08/25	Assembly Biosciences Announces Pricing of $175 Million in Equity Financings	AQ
08/08/25	Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes	AQ
06/08/25	Assembly Biosciences: Q2 Earnings Snapshot	AQ